Forum Topics IIQ IIQ Strawman interview with Chairm

Pinned straw:

Last edited a month ago

I took some notes from the interview as follows:

  •  IIQ's tests could become a platform for cancer detection. And this would be "disruptive".
  •  The way to market and reach researchers/interested institutions is changing. Now can use AI that searches every journal/phds for exosomes/markers etc. And send direct emails. Old way was to go to conferences.
  •  Some sort of merger seems likely. But didn't go into detail
  •  Stated there should be 'an uptick in sales from Jun - Dec 2024 for Exosome research isolation tool (Exo-Net). 

I spoke with Strawman after via emails. And we both think David got a bit sidetracked in the IIQ part of the chat.

I think if you are new to IIQ, I don't think David sold it particularly well. Also if you are doing research on IIQ, their website is terrible and does not explain their technology, apporach to market or the scale of the opportunity.

I would suggest it is best to look at some of their recent presentations like:


Also the interview with Alan Kohler is a little old now, but gives some good background (note they were called BARD1 previously BD1):


Things to look out for in the near future with IIQ:

  • SubB2M - Overian Cancer results. Preliminary results were amazing. These results will be from bigger sample size. The same SubB2M technology for Breast Cancer had a small decline in its effectiveness when it went from the preliminary results to the larger sample size. But still much better than anything currently on the market. So I am expecting these results to be similar to the results before. There are a bunch of other companies all striving for the same thing...but IIQ seems to be ahead or equal in terms of effectiveness and also more progressed in terms of hitting the market. Also works in an commercial lab...which makes it easier, cheaper and quicker to scale.
  • Exosome cancer tests - Not sure when these are coming. But exosomes are the future of medical detection of conditions. And potentially theraputics. So any great results in this area will be massive.
  • Exo-Net Revenue Sales - Today there was an annoucement INOVIQ and Promega sign Global EXO-NET Agreement . This is for the sale of the Exo-Net product. This is the best product on the market to isolate exosomes from blood samples. It is also the most scaleable product on the market. I don't expect big sales numbers. But should produce a fairly consistent revenue stream (thinking $200-500k a year). BUT - if one of these researchers, using Exo-Net, develops an exosome test, then IIQ gets a percntage share of that test.
  • Capital Raise/Acquisition - Based on the Strawman interview and the 2023 AGM discussion with David Williams, there will be a capital raise soon, and I think it may involve an aquisition and money to commercialise some of the IIQ SubB2M products.
  • Change in Management Team - I think there will be a change in the executive management. As IIQ moves into commercialisation, they will bring in a team to lead that type of work.

I'm hoping that 2024 is the year that IIQ can start to get some sales and build market share. I think of IIQ today, like PNV was about 6-8 years ago (not sure of the exact time frame). But it is early days....with a lot of promise. There are a lot of potential competitors....but when i cut through all their marketing BS....IIQ is def in a better position with better technology and more advanced.


John (aka Parko)

a month ago

I am just going to add here that BD1/IIQ are not the first to try and "platformise" exosomes. Exopharm (EX1) tried this and as far as I could ever tell the demand was just never there. While technically feasible and useful in theory, there was just no market for the product. IIQ have more irons in the fire, but if you are getting into this for the extracellular vesicule narratives please do yourselves a favor and figure out why Exopharm when down the tubes while holding successful and patented technology.


a month ago

Codiak Biosciences also declared bankrupt in 2023. They were also doing work on Exosomes.

Might be too hard to figure out mainly because of the lack of success from both EX1 as highlighted by @neke86_ and Codiak.

My only positive is seeing David Williams on the board, but he is there in a non-exec capacity.

I did hold EX1 in the past but sold when they made a error in one of their trials and had to start over.


a month ago

Interesting @edgescape and @neke86_

I'm sure there are many firms working on exosomes for many different applications. And I'm also sure that 99% of them will go nowhere.

The reason I like IIQ is because:

  • They have Exo-Net which is the best product on the market to extract the exosomes from a blood sample. And it is scalable. This is like selling shovels to miners during a gold rush. ;-)
  • A lot of companies are trying to use exosomes for theraputics (like EX1). IIQ have started to look at this, but their main focus has been on diagnotics. Which is faster to market.
  • They have other non-exosome tests coming to market soon which should start to provide revenue (SubB2M Breast and Overian).
  • The David Williams factor. If things are not progressing, I think David will make the appropriate changes (ie management) or acquisition.


a month ago

Hi @Parko5

I'm not trying to talk you out of an investment so don't get me wrong, but point one, exo-net, is exactly what I was referring to. EX1 had "LEAP", a revolutionary way to extract pure sterile exosomes in bulk, it was to be scalable, and serve as the 'platform' that major drugs companies would use. I was trying to highlight that the narrative is the same, but reworded.

I do like the diagnostics vs therapeutics angle though!

a month ago

Thanks John @Parko5 Do you happen to have an idea how these raises go - are they all a bit different or do they usually offer something to holders at a small discount to recent SP, like for example Ava did?


a month ago

Hi @lastever I assume it will be the normal route:

  • Institutional/large shareholders will get advanced info and be locked in before retail get a crack at a Share Purchase Plan.
  • In past raises with David Williams (like PNV) both groups will usually get the same terms (ie a discount to the last few months average SP and maybe some options).
  • David has also previously ensured that retail investors will get a Pro-Rata of their holding and have not sold shares to do the short term arbitrage game. He has also tried to exclude parties in the institutional part that have shorted.
  • The SPPs usually only allow retail to get $30k. Not sure why?

If you are after a large slice of IIQ in the them at and you might be able to get into the Institutional/large shareholder group.